The role of selenium in gut inflammation and Dysbiosis

Effect of Selenium supplementation in modulating Sarcopenia outcomes through Gut dysbiosis in Ulcerative Colitis patients - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/02/102849

Enrollment

Registered

2026-02-03

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K519- Ulcerative colitis, unspecified

Interventions

Intervention1: Selenium supplementation: selenium supplementation in the form of Selenomethionine will be given in the form of capsules dosage- 200 microgram per day for 3 months Control Intervention1

Eligibility

Inclusion criteria

Inclusion criteria: Patients with confirmed gut dysbiosis, sarcopenia and selenium deficiency in Ulcerative colitis patients

Exclusion criteria

Exclusion criteria: Females, co-morbidities (heart failure, diabetes mellitus, kidney disease and COPD) and patients on other diseases medications

Design outcomes

Primary

Measure	Time frame
The study aims to establish the role of Selenium supplementation in improving sarcopenia outcomes by modulating the gut dysbiosis in UC patientsTimepoint: baseline endpoint after 3 months	—

Secondary

Measure	Time frame
improved quality of LifeTimepoint: baseline endpoint after 3 months	—

Countries

India

Contacts

Public ContactGurseen Rakhra

Manav Rachna International Institute of Research and Studies

gurseen.fas@mriu.edu.in08368047368

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026